• Efficacy of intestinal sorbents in the comprehensive treatment of cholestatic hepatosis of pregnant women

Efficacy of intestinal sorbents in the comprehensive treatment of cholestatic hepatosis of pregnant women

PERINATOLOGY AND PEDIATRIC. UKRAINE. 2018.2(74):20-24; doi 10.15574/PP.2018.74.20

Lymanska A. Yu., Davydova Yu. V.
SI «Lukyanova Institute of Pediatrics, Obstetrics and Gynaecology of NAMS of Ukraine», Kyiv

Objective: to study the treatment efficacy and quality of life indicator in pregnants with cholestatic hepatosis.
Material and methods. Women with cholestatic hepatosis were divided into two groups. The 1st group consisted of 10 pregnant women who were administered conventional therapy (hepatoprotectors, intravenous fluid therapy, preparations of ursodeoxycholic acid). The 2nd group included 18 pregnant women who received in addition to conventional treatment Atoxil, 1 bottle (10 g of the drug in the form of aqueous suspension) thrice within 24 hours between meals, evenly distributing the indicated dose. Course duration of sorbents was 12–14 days. The quality of life indicator after comprehensive treatment was assessed using the special questionnaire «Gastrointestinal Simptom Rating Scale» (GSRS).
Results. Administration of intestinal sorbent Atoxil in the comprehensive treatment of cholestatic hepatosis allowed increasing the clinical and biochemical treatment efficacy of pregnant women. The advantage of this method of intestinal sorbent is the non-invasive nature of detoxification, which consists in the oral use of the sorbent, further binding and excretion of various toxic agents from the gastrointestinal tract, furthermore, stopping the enterohepatic circulation of endotoxins and hepatocyte destruction products and improving the antitoxic function of the liver. As a result of enterosorption, toxic and allergic reactions are weakened, metabolic loading on the organs of excretion (liver, intestine, kidneys, lungs, skin) is reduced, metabolic and immunological processes are improved, the permeability and integrity of the mucous membranes are restored, the intestinal circulation and the intestinal microflora composition are improved, dyspepsia and bowel function normalize, meteorism disappears.
Conclusions. High sorption activity of Atoxil, adsorption rate, safety and ease of use, absence of contraindications and the possibility of combination with other drugs allow individualizing disease management, avoiding the side effects and achieving high treatment efficiency while reducing its duration.
Key words: cholestatic hepatosis, pregnant, intestinal sorbents, Atoxil.


1. Medychna khimiia i klinichne zastosuvannia dioksydu kremniiu. (2003). Za red. akad. Chuiko AA. Kyiv: Naukova Knyha: 175—178.

2. Beuers U, Pusl T. (2006). Intrahepatic cholestasis of pregnancy — a heterogeneous group of pregnancy-related disorders? Hepatology. 43: 647—649. https://doi.org/10.1002/hep.21156; PMid:16557565

3. Fagan EA. (2002). Intrahepatic cholestasis of pregnancy. Clin Liver Dis. 3: 603—632. https://doi.org/10.1016/S1089-3261(05)70087-8

4. Fagan EA. (2002). Intrahepatic cholestasis of pregnancy. Clin. Liver Dis. 3: 603—632. https://doi.org/10.1016/S1089-3261(05)70087-8

5. Germain AM, Carvajal JA, Glasinovic JC et al. (2002). Intrahepatic cholestasis of pregnancy: an intriguing pregnancy-specific disorder. J. Soc. Gynecol. Investig. 9: 10—14. https://doi.org/10.1177/107155760200900103; https://doi.org/10.1016/S1071-5576(01)00144-7

6. Lammert F, Marschall HU, Glantz A, Matern S (2000). Intrahepatic cholestasis of pregnancy: molecular pathogenesis, diagnosis and management. J. Hepatol. 2000. 33: 1012—1021. https://doi.org/10.1016/S0168-8278(00)80139-7

7. Nichols AA. (2005). Cholestasis of pregnancy: a review of the evidence. J. Perinat. Neonatal. Nurs. 19: 217—225. https://doi.org/10.1097/00005237-200507000-00007; PMid:16106229

8. Pauli-Magnus C, Meier PJ, Stieger B. (2010). Genetic determinants of druginduced cholestasis and intrahepatic cholestasis of pregnancy. Semin. Liver Dis. 30; 2: 147—159. https://doi.org/10.1055/s-0030-1253224; PMid:20422497

9. Pusl Т, Beuers U. (2007). Intrahepatic cholestasis of pregnancy. Orphanet J. Rare Dis. 2: 26.

10. Reyes H, Sjovall J. (2003). Bile acids and progesterone metabolites in intrahepatic cholestasis of pregnancy. Ann. Med. 32; 2: 94—106. https://doi.org/10.3109/07853890009011758

11. Roponen A. (2006). Intrahepatic cholestasis of pregnancy — genetic background, epidemiology and hepatobiliary consequences. Academic Dissertation. — Helsinki University Central Hospital.

12. Tribe RM, Dann AT, Kenyon AP et al. (2010). Longitudinal profiles of 15 serum bile acids in patients with intrahepatic cholestasis of pregnancy. Am. J. Gastroenterol. 105; 3: 585—595. https://doi.org/10.1038/ajg.2009.633; PMid:19904249

13. Zecca E. (2006). Intrahepatic cholestasis of pregnancy and neonatal respiratory distress syndrome. Pediatrics. 117: 1669—1672. https://doi.org/10.1542/peds.2005-1801; PMid:16651322